Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S, Bissonnette R, Armstrong AW, Seneschal J, Eyerich K, Estrada YD, Bose SN, Xu D, Chen A, Tatulych S, Güler E, Chan G, Page KM, Kerkmann U. Guttman-Yassky E, et al. Among authors: guler e. Allergy. 2024 May;79(5):1258-1270. doi: 10.1111/all.15969. Epub 2023 Dec 18. Allergy. 2024. PMID: 38108208 Clinical Trial.
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP, Bewley A, Ständer S, Castro C, Misery L, Kim BS, Biswas P, Chan G, Myers DE, Watkins M, Alderfer J, Güler E, Silverberg JI. Thyssen JP, et al. Among authors: guler e. Dermatology. 2024;240(2):243-253. doi: 10.1159/000535285. Epub 2023 Dec 11. Dermatology. 2024. PMID: 38081155 Free PMC article. Clinical Trial.
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.
Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Bärenfaller K, Behrendt H, Bieber T, Bigliardi P, Bigliardi-Qi M, Bonefeld CM, Bösch S, Brüggen MC, Diemert S, Duchna HW, Fähndrich M, Fehr D, Fellmann M, Frei R, Garvey LH, Gharbo R, Gökkaya M, Grando K, Guillet C, Guler E, Gutermuth J, Herrmann N, Hijnen DJ, Hülpüsch C, Irvine AD, Jensen-Jarolim E, Kong HH, Koren H, Lang CCV, Lauener R, Maintz L, Mantel PY, Maverakis E, Möhrenschlager M, Müller S, Nadeau K, Neumann AU, O'Mahony L, Rabenja FR, Renz H, Rhyner C, Rietschel E, Ring J, Roduit C, Sasaki M, Schenk M, Schröder J, Simon D, Simon HU, Sokolowska M, Ständer S, Steinhoff M, Piccirillo DS, Taïeb A, Takaoka R, Tapparo M, Teixeira H, Thyssen JP, Traidl S, Uhlmann M, van de Veen W, van Hage M, Virchow C, Wollenberg A, Yasutaka M, Zink A, Schmid-Grendelmeier P. Traidl-Hoffmann C, et al. Among authors: guler e. Allergy. 2024 Oct;79(10):2605-2624. doi: 10.1111/all.16247. Epub 2024 Aug 4. Allergy. 2024. PMID: 39099205 Free article. Review.
Investigation of the Protective Effects of Dexmedetomidine, Midazolam, Propofol, and Intralipid on Oxidative Stress and Inflammation in Rats with Lidocaine-Induced Toxicity.
Kucun MK, Guler EM, Saracoglu A, Yildirim M, Demirtas C, Serdogan F, Beyaztas H, Aktas S, Kacan M, Gaszynski T, Ratajczyk P, Saracoglu KT. Kucun MK, et al. Among authors: guler em. J Inflamm Res. 2025 Jan 10;18:431-443. doi: 10.2147/JIR.S493566. eCollection 2025. J Inflamm Res. 2025. PMID: 39816952 Free PMC article.
513 results